The impact of host factors on management of hepatitis c virus

Hepatitis Monthly

Volumn 12, Issue 4, 2012, Pages 235-241

  Khattab, Mahmoud Aboelneen ^a   Eslam, Mohammed ^a  

^a MINIA UNIVERSITY   (Egypt)

Author keywords

Hepatitis c virus; Host factors; Liver diseases

Indexed keywords

2', 5' OLIGOADENYLATE SYNTHETASE; CHOLESTEROL; HOST FACTOR; INSULIN RECEPTOR; INTERLEUKIN 28B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYXOVIRUS RESISTANCE PROTEIN A; PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RIBAVIRIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AGE; ANTIVIRAL THERAPY; ARTICLE; FATTY LIVER; FIBROSIS; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIVER CIRRHOSIS; MENOPAUSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS REPLICATION;

EID: 84861152218     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.5883     Document Type: Article

References (71)

1. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A. 1991;88(8):3392.
2. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 1994;19(5):1321-1324.
3. Kuiken C, Simmonds P. Nomenclature and numbering of the hepatitis C virus. Methods Mol Biol. 2009;510:33-53.
4. Organization WH. Hepatitis C. [updated] Geneva, Switzerland World Health Organization, 2000 WHO fact sheet 164; Available from: http://www.who.int/mediacentre/factsheets/fs164/en/print.html.
5. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36(5 Suppl 1):S47-S56.
6. Seef LB. Natural history of hepatitis C. Hepatology. 1997;26(S3):21S-28S.
7. Ghany MG, Strader DB, Thomas DL, Seef LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374.
8. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology. 2004;39(4):880-90.
9. Khattab MA. Targeting host factors: a novel rationale for the management of hepatitis C virus. World J Gastroenterol. 2009;15(28):3472-9.
10. Asahina Y, Izumi N, Uchihara M, Noguchi O, Nishimura Y, Inoue K, et al. Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens. J Hepatol. 2003;39(3):421-7.
11. Suzuki F, Arase Y, Suzuki Y, Tsubota A, Akuta N, Hosaka T, et al. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat. 2004;11(3):271-6.
12. Knapp S, Yee LJ, Frodsham AJ, Hennig BJ, Hellier S, Zhang L, et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 2003;4(6):411-9.
13. Mueller T, Gessner R, Sarrazin C, Graf C, Halangk J, Witt H, et al. Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1. Hepatology. 2003;38(6):1592; author reply -3.
14. Schiemann U, Glas J, Torok P, Simperl C, Martin K, Konig A, et al. Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism. Digestion. 2003;68(1):1-4.
15. Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleu-kin-10, tumor necrosis factor-[alpha], and transforming growth factor-[beta] 1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol. 2002;36(2):271-277.
16. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399-401.
17. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gas-troenterology. 2010;138(7):2307-2314.
18. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105-1109.
19. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798-801.
20. Asselah T, Essioux L, Marcellin P, Fried MW, Jensen DM, Germer S, et al. 1180 A chromosome 19 snp (rs12979860) predicts outcome (evr/svr) in hcv patients treated with interferon, independent of pegylation or ribavirin. J Hepatol. 2010;52:S456.
21. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained viro-logic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120-129 e18.
22. Romero-Gomez M, Eslam M, Ruiz A, Maraver M. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int. 2011;31(4):443-460.
23. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010;139(3):821-827, 7 e1.
24. Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-nave patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9(4):344-350.
25. Iadonato SP, Katze MG. Genomics: Hepatitis C virus gets personal. Nature. 2009;461(7262):357-358.
26. Reddy KR, Messinger D, Popescu M, Hadziyannis SJ. Peginter-feron alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat. 2009;16(10):724-731.
27. Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci. 2009;54(6):1317-1324.
28. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol. 2011;45(2):e17-e24.
29. Ginaldi L, Loreto MF, Corsi MP, Modesti M, De Martinis M. Im-munosenescence and infectious diseases. Microbes Infect. 2001;3(10):851-857.
30. Ishizaka N, Ishizaka Y, Takahashi E, Tooda E, Hashimoto H, Nagai R, et al. Association between hepatitis C virus seropositiv-ity, carotid-artery plaque, and intima-media thickening. The Lancet. 2002;359(9301):133-135.
31. Commentary A, Interactive F, Page P, Video F. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
32. Eslam M, Khattab MA, Harrison SA. Insulin resistance and hepatitis C: an evolving story. Gut. 2011;60(8):1139-1151.
33. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut. 2006;55(1):123-130.
34. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fbrosis. Gastroenterology. 2008;134(2):416-423.
35. Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginter-feron/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol. 2010;105(9):1970-1977.
36. Grasso A, Malfatti F, Leo PD, Martines H, Fabris P, Toscanini F, et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol. 2009;51(6):984-990.
37. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128(3):636-641.
38. Mizuta T, Kawaguchi Y, Eguchi Y, Takahashi H, Ario K, Akiyama T, et al. Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Digestive diseases and sciences. 2010;55(1):183-189.
39. Poustchi H, Negro F, Hui J, Cua IHY, Brandt LR, Kench JG, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol. 2008;48(1):28-34.
40. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165(5):1499.
41. Pazienza V, Clément S, Pugnale P, Conzelman S, Foti M, Mangia A, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype specifc mechanisms. Hepatology. 2007;45(5):1164-1171.
42. Persico M, Capasso M, Russo R, Persico E, Croce L, Tiribelli C, et al. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Gut. 2008;57(4):507.
43. Bernsmeier C, Duong FHT, Christen V, Pugnale P, Negro F, Terrac-ciano L, et al. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J Hepa-tol. 2008;49(3):429-440.
44. Vanni E, Abate ML, Gentilcore E, Hickman I, Gambino R, Cassader M, et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology. 2009;50(3):697-706.
45. Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 2003;17(3):488-490.
46. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut. 2006;55(4):529-535.
47. Huang Y, Feld JJ, Sapp RK, Nanda S, Lin JH, Blatt LM, et al. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology. 2007;132(2):733-744.
48. Miyaaki H, Ichikawa T, Nakao K, Matsuzaki T, Muraoka T, Honda T, et al. Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C. Hepatol Res. 2009;39(9):850-855.
49. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystro-phic and ob/ob mice. Mol Cell. 2000;6(1):77-86.
50. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat cell biol. 2007;9(9):1089-1097.
51. Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, et al. Pioglitazone improves virological response to peginterferon 2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int. 2010;30(3):447-454.
52. Konishi I, Horiike N, Hiasa Y, Tokumoto Y, Mashiba T, Michitaka K, et al. Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Hepatol Res. 2007;37(5):331-336.
53. Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci. 2009;54(12):2699-2705.
54. Kita Y, Mizukoshi E, Takamura T, Sakurai M, Takata Y, Arai K, et al. Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus. Metabolism. 2007;56(12):1682-1688.
55. Petta S, Camma C, Di Marco V, Alessi N, Cabibi D, Caldarella R, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol. 2008;103(5):1136-1144.
56. Mawatari H, Yoneda M, Fujita K, Nozaki Y, Shinohara Y, Sasaki H, et al. Association between lipoprotein subfraction profile and the response to hepatitis C treatment in Japanese patients with genotype 1b. J Viral Hepat. 2010;17(4):274-279.
57. Lange CM, von Wagner M, Bojunga J, Berg T, Farnik H, Hassler A, et al. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-a-2a and ribavirin. Eur J Gastroenterol Hepatol. 2010;22(11):1303.
58. Jaeckel E, Zehnter E, John C, Lutz T, Schmidt W, Link R, et al. 266 clinical markers of the metabolic syndrome are associated with hcv genotype 1 infection and are strong negative predictors of early virological response. J Hepatol. 2010;52:S112-S.
59. Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, Belle SH, et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology. 2010;52(3):854-863.
60. Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology. 2010;52(3):864-874.
61. Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol. 2011;55(5):980-988.
62. Li JH, Qian Lao X, Tillmann HL, Rowell J, Patel K, Thompson A, et al. Interferon lambda genotype and low serum low density lipo-protein cholesterol levels in patients with chronic hepatitis C infection. Hepatology. 2010;51(6):1904-1911.
63. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int. 2009;29(Suppl 2):26-37.
64. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and f-brosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130(6):1636-1642.
65. Khattab MA, Abdel-fattah ME, Eslam M, Abdelaleem A, Abdelal-eem RA, Shatat M, et al. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy. J Clin Gastroenterol. 2010;44(10):707-712.
66. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeu-zem S, et al. Effect of treatment with peginterferon or interferon alfa 2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38(1):75-85.
67. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3* 1,* 2. J Hepatol. 2004;40(6):993-999.
68. Westin J, Lagging M, Dhillon AP, Norkrans G, Romero A, Paw-lotsky JM, et al. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat. 2007;14(1):29-35.
69. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fbrosis progression in chronic hepatitis C. Gut. 2005;54(7):1003.
70. Villa E, Karampatou A, Camma C, Di Leo A, Luongo M, Ferrari A, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology. 2011;140(3):818-829.
71. Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, et al. Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel. J Hepatol. 2010;54(6):1250-1262.